1. Scrip
  2. >>Drug Pricing

Excessive Drug Pricing: What It Is, And What It Isn't

 
• By Ian Schofield

It's difficult to know exactly how to define "excessive" or "unfair" pricing where pharmaceutical products are concerned, and many factors have to be taken into account. Even the EU Commission and competition authorities may be reluctant to pursue cases of alleged price gouging, lawyer David Hull told Informa's recent EU Pharma Law Forum in Brussels.

business card

Excessive pricing of medicines is never far from the public eye, particularly in times of pressure on healthcare spending, and all the more so since the furore over Martin Shkreli's decision to raise the US price of Turing Pharmaceuticals AG's toxoplasmosis drug Daraprim by more than 5,000% in 2015.

Shkreli's move was certainly an eye-catching maneuver, and one that most in the pharmaceutical company industry were quick to distance...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Drug Pricing

Lilly/Novo Get Priority Reviews For Lowering Drug Prices

 
• By Jessica Merrill

Novo Nordisk’s high-dose semaglutide for obesity and Lilly’s oral obesity candidate orforglipron were given priority review vouchers by the US Food and Drug Administration.

Lilly, Novo Lower US Obesity Drug Prices To Secure Government Coverage

 
• By Jessica Merrill

Wegovy and Zepbound will cost around $250 per month under Medicare and Medicaid, and the drugs will cost around $350 per month through TrumpRx.

AstraZeneca Stays Coy On US Pricing Deal Impact

 
• By Andrew McConaghie

Another strong quarter keeps AstraZeneca on track to meet its $80bn sales ambition, and its CEO maintains the recent Trump deal provides pricing reassurance, despite a lack of details so far.

McKinsey Execs On Perfecting The US Launch Recipe, Do’s For First-Time Launchers

 
• By Anju Ghangurde

Senior McKinsey executives discuss how biopharma can ace its US launch strategy and first-time launchers can stack the odds in their favor amid complex market dynamics including the MFN pricing push.

More from Scrip

Lilly’s Eloralintide Success Sets Bar For Amylin Rivals

 
• By Andrew McConaghie

The US pharma giant may have a best-in-class amylin agonist to go with incretin blockbuster Zepbound, but challengers could still go one better on safety and tolerability.

Bavarian Nordic Future Looks Bright Despite Failed Takeover Bid

 
• By Kevin Grogan

Even with Innosera's sweetened offers and a boardroom recommendation, the proposed acquisition could not clear the minimum 66.67% shareholder approval level.

Centessa’s Sleep Disorder Drug Shows Broad Potential But Faces Tough Competition

 
• By Sushmita Panda

Pivotal data next year will be key for the early-stage biotech as analysts remain divided on ORX750's potential.